On May 14, 2024, SeaStar Medical Holding Corporation, a medical device company listed on Nasdaq under the symbol ICU, announced its financial results for the first quarter ended March 31, 2024. The announcement was made through a press release and included in the company's Form 8-K filing with the SEC. SeaStar Medical's CEO, Eric Schlorff, highlighted the upcoming commercial launch of Quelimmune™ Pediatric for treating pediatric patients with acute kidney injury (AKI) and sepsis, with initial sales expected in the coming weeks. The company has also made progress in its NEUTRALIZE-AKI clinical trial for its Selective Cytopheretic Device Adult (SCD-ADULT) and has strengthened its balance sheet by eliminating senior secured debt, ending the quarter with $5 million in cash. The company...Show More

On May 14, 2024, SeaStar Medical Holding Corporation, a medical device company listed on Nasdaq under the symbol ICU, announced its financial results for the first quarter ended March 31, 2024. The announcement was made through a press release and included in the company's Form 8-K filing with the SEC. SeaStar Medical's CEO, Eric Schlorff, highlighted the upcoming commercial launch of Quelimmune™ Pediatric for treating pediatric patients with acute kidney injury (AKI) and sepsis, with initial sales expected in the coming weeks. The company has also made progress in its NEUTRALIZE-AKI clinical trial for its Selective Cytopheretic Device Adult (SCD-ADULT) and has strengthened its balance sheet by eliminating senior secured debt, ending the quarter with $5 million in cash. The company provided updates on its commercial and development programs, including the receipt of U.S. regulatory approval for Quelimmune under a humanitarian device exemption and the advancement of its SCD technology for various indications. Financially, SeaStar Medical reported a net loss of $12.7 million for the quarter, or $0.19 per share, and an increase in cash to $5.0 million, bolstered by a $9.0 million registered direct offering.